MV 088
Alternative Names: MV 088Latest Information Update: 04 Feb 2021
At a glance
- Originator Kunming Pharmaceutical
- Class Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Postmenopausal osteoporosis
Most Recent Events
- 17 Dec 2020 Preclinical trials in Postmenopausal osteoporosis in China (SC) Before December 2020
- 17 Dec 2020 Kunming Pharmaceuticals plans a phase I trial for Postmenopausal osteoporosis (In volunteers ) in February 2021 (NCT04673799) (CTR20202419 ) (KYJT-MV088-I01)